Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.amjcard.2017.10.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A European Delphi Consensus on the Management of Abdominal Aortic Aneurysms in Patients with Heritable Aortic Diseases.
Eur J Vasc Endovasc Surg
January 2025
Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain; Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain; Department of Vascular, Endovascular Surgery and Angiology, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Electronic address:
Objective: Abdominal aortic aneurysm (AAA) in a patient with an underlying heritable aortic disease (HAD) is rare, and evidence based recommendations for its management are lacking. This study aimed to generate a consensus from multidisciplinary specialists on the diagnosis, treatment, and surveillance of AAA associated with HAD and to define topics of interest for future research.
Methods: A Delphi consensus was designed involving European multidisciplinary specialists and reported using the ACcurate COnsensus Reporting Document (ACCORD) reporting guideline.
Expert Opinion on Managing Adverse Reactions Associated With Acalabrutinib Therapy: A Delphi Consensus From France.
Clin Lymphoma Myeloma Leuk
October 2024
Department of Pharmacy, Paris Public Hospital at Home (HAD AP-HP), University Hospitals of Paris, Paris, France.
Article Synopsis
- - Acalabrutinib, a more advanced treatment for chronic lymphocytic leukemia, has a better safety profile than older drugs but lacks clear guidelines on managing its side effects, prompting a study to establish best practices.
- - A team of medical professionals across France found that hospital pharmacists should evaluate drug interactions before starting patients on acalabrutinib and advised against using it with certain medications that can increase risks of toxicity or reduce effectiveness.
- - The study highlighted the need for monitoring blood pressure during treatment, outlined protocols for managing procedures, and suggested headache management strategies, demonstrating the importance of teamwork in improving patient care while using acalabrutinib.
Cardiovascular disease - risk assessment and reduction: NICE 2023 update for GPs.
Br J Gen Pract
November 2024
GP cardiologist, and National Institute for Health and Care Research (NIHR) academic clinical lecturer, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford.
A Delphi consensus project to capture experts' opinion on hyperkalaemia management across the cardiorenal spectrum.
ESC Heart Fail
October 2024
Nephrology Department, Army Share Fund Hospital of Athens, Athens, Greece.
The main purpose of this project was to capture experts' opinion on hyperkalaemia management and form best practice recommendations for cardiorenal patients in Greece. A steering committee of nephrologists and cardiologists developed 37 statements. An online questionnaire completed by 32 experts in cardiorenal management in Greece.
View Article and Find Full Text PDFManagement of heart disease in renal transplant recipients: a national Delphi survey-based SET/SEC/SEN consensus document.
Rev Esp Cardiol (Engl Ed)
October 2024
Servicio de Nefrología, Hospital Universitario de Canarias, Santa Cruz de Tenerife, National Network for Kidney Research RICORS2040 RD21/0005/0012, Instituto de Tecnologías Biomédicas, Universidad de La Laguna, Santa Cruz de Tenerife, Spain. Electronic address:
Renal transplantation improves the survival and quality of life of patients with end-stage renal disease. Cardiovascular disease is the leading cause of morbidity and mortality in renal transplant recipients. The bidirectional relationship between renal and heart disease creates a unique clinical scenario that demands a comprehensive and personalized approach.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!